

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION
WASHINGTON, D.C. 20580

Office of the Secretary

August 26, 2013

Michael F. Brockmeyer, Esq.
Counsel For Shire plc
Frommer Lawrence & Haug LLP
1667 K Street, NW
Washington, DC 20006

Re: Shire plc, FTC File No. 121-0072

Dear Mr. Brockmeyer:

The Federal Trade Commission's Bureau of Competition has been conducting a nonpublic investigation to determine whether Shire or its affiliates, Teva Pharmaceutical Industries Ltd. or its affiliates, or any other unnamed persons, partnerships, or corporations have engaged or are engaging in conduct that violates Section 5 of the Federal Trade Commission Act, as amended, 15 U.S.C. § 45, with respect to the market for Adderall XR and its generic equivalents, or other products treating attention deficit hyperactivity disorder.

Upon further review of this matter, it now appears that no further action is warranted by the Commission at this time. Accordingly, the investigation has been closed. This action is not to be construed as a determination that a violation may not have occurred, just as the pendency of an investigation should not be construed as a determination that a violation has occurred. The Commission reserves the right to take such further action as the public interest may require.

By direction of the Commission.

Donald S. Clark
Secretary